Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors
December 16 2019 - 6:59AM
Business Wire
Three Independent Directors Bring Significant
Pharmaceutical, Healthcare and Financial Expertise and Track
Records of Creating Value for Shareholders
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the
“Company”) today announced that Jeff George, John Kiely and Shlomo
Yanai have been appointed to the Company’s Board of Directors,
effective as of December 14, 2019. These three new independent
directors bring to Amneal extensive records of overseeing growth
and creating value in the pharmaceutical and healthcare
industries.
Paul Meister, Chairman of Amneal’s Board, said, “It is a
testament to the opportunities ahead for Amneal that we have
attracted leaders of Jeff, John and Shlomo’s caliber to our Board.
They each have deep knowledge of our industry, and we are confident
they will help us capitalize on those opportunities. Moving
forward, we will continue to add new expertise and fresh
perspectives to our Board.”
Amneal Co-Founders and Co-Chief Executive Officers, Chirag Patel
and Chintu Patel, said, “Jeff, John and Shlomo each bring
tremendous records of leadership and delivering results in the
global pharmaceutical and healthcare industries, and we are pleased
to welcome them to the Amneal Board. We look forward to working
closely with them as we execute on our strategies to reinvigorate
Amneal, drive growth and create value for patients, shareholders
and our other stakeholders.”
Select leadership and industry experience for Amneal’s three new
directors includes:
- Jeff George has nearly 20 years of global healthcare and
corporate leadership experience across North America, Europe and
emerging markets. He currently serves as Managing Partner of Maytal
Capital, a private equity investment and advisory firm he founded,
as well as an Operating Partner at Revival Healthcare Capital, a
medical-device private equity firm. Among other leadership roles,
Mr. George previously served as Division Head and CEO of Sandoz,
Novartis’ $10 billion generic pharmaceuticals and biosimilars
subsidiary, from 2008 to 2014; as Division Head and CEO of Alcon,
Novartis’ then $10 billion branded eye care business, from 2014 to
2016; and more recently as CEO and board member of Performance
Health, the largest global manufacturer and distributor of products
to the physical therapy and rehabilitation markets. He currently
serves on the board of Silicon Valley-based healthcare software
firm Roam Analytics and previously served on the boards of AdvaMed
(the Advanced Medical Technology Association) and Performance
Health Holdings.
- John Kiely has more than 35 years of financial
leadership and advisory experience serving public companies,
including multi-national corporations. Until June 2019 he served as
Senior Assurance Partner at Pricewaterhouse Coopers, where he
focused on the pharmaceutical, manufacturing chemical and medical
device sectors. Since 1980, he has held various roles of increasing
responsibility at Pricewaterhouse Coopers, including as U.S.
Pharmaceutical Leader and Global Pharmaceutical Assurance Leader.
Mr. Kiely currently serves on the board at Zovio, Inc.
- Shlomo Yanai has more than 15 years of corporate
leadership experience, primarily in the pharmaceutical industry. He
most recently served as President and CEO at Teva Pharmaceutical
Industries Ltd., from 2007 to 2012, where he increased revenues
from $8.4 billion in 2006 to $18.3 billion in 2011, and net profit
from $1.9 billion to $4.4 billion over the same time period. Mr.
Yanai also serves as an advisor to CVC Capital Partners, a leading
private equity firm with $80.5 billion in assets under management.
In addition, he currently serves on the boards of PDL BioPharma
Inc. and WR Grace & Co. Mr. Yanai previously served on the
boards of Cambrex Corp., Lumenis Ltd., Perrigo Company and Sageant
Pharmaceuticals, among others, and held various leadership
positions in the Israel Defense Forces.
Amneal also announced today that Jean Selden Greene has retired
from the Amneal Board, effective as of December 14, 2019. Ms.
Greene's resignation was not based on any disagreement with the
Company on any matter relating to the Company’s operations,
policies or practices. As a result of the foregoing changes on
Board composition, the Board will comprise eleven directors.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in
Bridgewater, NJ, is a fully-integrated pharmaceutical company
focused on the development, manufacture and distribution of generic
and specialty drug products. The Company has manufacturing
operations in North America, Asia, and Europe, working together to
bring high-quality medicines to patients primarily within the
United States.
Amneal has an extensive portfolio of more than 225 marketed
commercial products and is expanding its portfolio to include
complex dosage forms, including biosimilars, in a broad range of
therapeutic areas. The Company also markets a portfolio of branded
pharmaceutical products through its Specialty segment focused
principally on central nervous system and endocrine disorders. For
more information, visit www.amneal.com.
Forward-Looking Statements
Certain statements contained herein, regarding matters that are
not historical facts, may be forward-looking statements (as defined
in the Private Securities Litigation Reform Act of 1995, as
amended). Such forward-looking statements include statements
regarding management’s intentions, plans, beliefs, expectations or
forecasts for the future, including, among other things, future
operating results and financial performance, product development
and launches, integration strategies and resulting cost reduction,
market position and business strategy. Words such as “may,” “will,”
“could,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “assume,” “continue,” and similar words are intended to
identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking
statements. These forward-looking statements are based on current
expectations of future events. If the underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Amneal. A list and descriptions of these risks,
uncertainties and other factors can be found in the Company’s most
recently filed Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, as supplemented by any subsequently filed
Quarterly Reports on Form 10-Q. Copies of these filings are
available online at www.sec.gov, www.amneal.com or on request from
the Company.
Forward-looking statements included herein speak only as of the
date hereof and we undertake no obligation to revise or update such
statements to reflect the occurrence of events or circumstances
after the date hereof, except as otherwise required by United
States securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191216005337/en/
Todd Branning Chief Financial Officer 908-280-6019
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024